Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer.

Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. · 2022

Read Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. by Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9623991.txt.

Introduction

Han and co-authors summarize the machinery of exosome biogenesis and its use as a cancer drug target. Exosomes are key couriers between cells in health and disease. Their making runs through four main steps in sequence. Cargo sorting comes first, then vesicle body formation. Transport and fusion with the cell surface close the chain.

Each step can run by more than one mechanism. ESCRT dependent and independent routes both appear. Ceramide and tetraspanin paths add further variety. Mixed routes explain why exosome groups are so uneven. Cancer cells hijack the system for their own gain. They tweak gene output, protein marks, and signals to reshape output. The review sorts those tricks by step and player. Drug plans that strike exosome making are then weighed. Such plans may slow spread and drug resistance, they argue.

Catalog record

CREATORHan QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE131 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9623991

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer By Qing-Fang Han, Wen-Jia Li, Kai-Shun Hu, Jie Gao, Wen-Long Zhai, Jing-Hua Yang, Shui-Jun Zhang Published in: Molecular Cancer DOI: 10.1186/s12943-022-01671-0 ABSTRACT Abstract Exosomes are well-known key mediators of intercellular communication and contribute to various physiological and pathological processes. Their biogenesis involves four key steps, including cargo sorting, MVB formation and maturation, transport of MVBs, and MVB fusion with the plasma membrane. Each process is modulated through the competition or coordination of multiple mechanisms, whereby diverse repertoires of molecular cargos are sorted into distinct subpopulations of exosomes, resulting in the high heterogeneity of exosomes. Intriguingly, cancer cells exploit various strategies, such as aberrant gene expression, posttranslational modifications, and altered signaling pathways, to regulate the biogenesis, composition, and eventually functions of exosomes to promote cancer progression. Therefore, exosome biogenesis-targeted therapy is being actively explored. In this review, we systematically summarize recent progress in understanding the machinery of exosome biogenesis and how it is regulated in the context of cancer. In particular, we highlight pharmacological targeting of exosome biogenesis as a promising cancer therapeutic strategy. Keywords: Exosomes, Biogenesis, Regulation, Implications, Cancer BACKGROUND Exosomes are extracellular vesicles with a diameter of ~ 30–150 nm that are secreted by the fusion of multivesicular bodies (MVBs) with the plasma membrane [1]. Since they were first visualized and described in the 1980s [2, 3], especially in the last 10 years, the field of exosome research has developed rapidly. Exosomes contain various cargos, such as proteins, lipids, and nucleic acids, including messenger RNAs, noncoding RNAs, and DNA [4]. By exchanging functional contents between cells, exosomes play fundamental roles in maintaining homeostasis and combatting stress. Many studies have shown that exosomes are involved in a variety of tumor-promoting activities, including anti-apoptosis, metastasis, angiogenesis, immune evasion and chemoresistance. These functions have been well reviewed from various perspectives, such as the type of donor cells or category of contents [5–9]. However, the molecular mechanisms of exosome biogenesis, especially how these mechanisms are exploited by cancer cells, has been less intensively investigated. Generally, MVBs are derived by endocytosis, during which multiple mechanisms mediate the inward budding of the plasma membrane and the formation of early endosomes. After recycling a subset of proteins back to the plasma membrane, early endosomes subsequently incorporate various cargo into intraluminal vesicles (ILVs) to generate MVBs. Following their maturation, MVBs can dynamically communicate with other organelles by various paths, such as releasing and taking up vesicles from the trans-Golgi network (TGN) and making direct contact with the endoplasmic reticulum (ER), mitochondrion, or phagosome [10–13]. All these communications modulate the formation of MVBs and the molecular composition of ILVs. Eventually, mature MVBs either fuse with lysosomes to be degraded or fuse with the plasma membrane to release ILVs, so-called exosomes (Fig. 1). [Figure: Overview of the process for exosome biogenesis. MVBs take the center of exosome biogenesis. Generally, MVBs are derived from endocytosis, during which different mechanisms mediate the inward budding of the plasma membrane and the formation of early endosomes. MVBs can dynamically communicate with other organelles or compartments including trans-Golgi network (TGN), endoplasmic reticulum (ER), mitochondrion, phagosome, RNA granule and micronuclei, et al. Therefore, different repertoires of cargos such as proteins, RNAs, DNAs or lipids are sorted into MVBs. After the maturation of MVBs, they can either fuse with lysosome to be degraded or fuse with plasma membrane to release ILVs, the so-called exosomes. Of note, MVB can fuse with autophagosome to form amphisome, which can either fuse with lysosome to be degraded or fuse with plasma membrane to secret exosomes] Briefly, exosome biogenesis consists of four steps: cargo sorting to MVBs, MVB formation, transport of MVBs, and MVB-plasma membrane fusion. Each step of exosome biogenesis is mediated by multiple mechanisms, which are highly variable depending on cargo, cell type, and microenvironment and which lead to the heterogeneity of exosomes. In particular, distinct mechanisms are not mutually exclusive, but can be employed by the same MVB. The same type of cargo can adopt different mechanism to mediate exosome sorting. Importantly, cancer cells can exploit multiple strategies to modulate exosome biogenesis and change the composition and function of exosomes, thereby favoring the release of tumor-promoting exosomes. Herein, we summarize recent progress in understanding the machinery of exosome biogenesis and how this machinery is regulated in cancer. In addition, we provide a comprehensive overview of strategies and inhibitors targeting exosome biogenesis and highlight the perspective of pharmacological targeting of exosome generation in cancer therapy. Throughout, we highlight the key, perplexing questions that prevent us from understanding exosome biogenesis and limit the therapeutic implications of targeting exosome biogenesis. The machinery of MVB formation MVB formation is at the center of exosome biogenesis. Particularly, membrane budding and ILV generation are key activities in this process [14]. Until recently, multiple mechanisms were proposed to drive the budding of limiting membrane and generation of ILVs (Fig. 2). Generally, the mechanisms consist of endosomal sorting complex required for transport (ESCRT)-dependent and ESCRT-independent pathways. [Figure: Multiple mechanisms regulate the formation of ILVs. MVBs are characterized by containing intralumenal vesicles which can be controlled by multiple mechanisms. Generally, they can be divided into two categories which are ESCRT-dependent pathway and ESCRT-independent pathway. For the classical ESCRT-dependent pathways, ESCRT-0, -I, -II, -III subcomplexes and ATPase VPS4 cooperate in a stepwise manner to mediate the ILV formation (1). For the non-canonical ESCRT-dependent pathways, HD-PTP (2) or Alix (3) can both recognize specific cargos and recruit ESCRT-III and VPS4 to limiting membrane of MVBs, during which other ESCRT subcomplexes are not indispensable. In addition, several other proteins or pathways especially components of lipid rafts paly crucial roles in ESCRT-independent ILV formation. For example, CD63 could promote ILV formation by both ESCRT and ceramide-independent mechanism; nSMase2-ceramide pathway could drive ILV formation and MVB sorting of cargos such as PE-conjugated LC3 and its binding partners in an ESCRT-independent mechanism. Moreover, caveolin-1 or flotillins could drive lipid raft dependent ILV formation, during which process nSMase-ceramide pathway is required in some cell lines. Specially, F-actin formation on the limiting membrane of MVBs that was regulated by S1P signaling promotes ILV sorting of cargos, though the precise role of F-actin formation during the generation of ILVs is still elusive] ESCRT-dependent pathway ESCRT is well studied and best described for its function in membrane budding and ILV formation [15]. ESCRT consists of ESCRT-0, -I, -II, -III subcomplexes and the ATPase VPS4, which cooperate in a stepwise manner. ESCRT-0 composed of Hrs and STAM recognizes mono- or poly-ubiquitylated cargo proteins via their ubiquitin-binding domain. In addition, the FYVE domain of ESCRT-0 binds endosomal lipid phosphatidylinositol 3-phosphate (PI3P) through which to capture cargos to clathrin-coated microdomain on the limiting membrane. Subsequently, ESCRT-I and -II are recruited, and they cooperate to form a saddle-shaped protein complex that is important for the ESCRT-III assembly [16]. Following ATP hydrolysis by VPS4, ESCRT-III subunits undergo sequential polymerization and drive membrane deformation and fission to ultimately produce ILV [17]. Notably, the ESCRT complex recruits deubiquitinating enzymes that remove ubiquitin from cargo proteins accompanied by their incorporation into ILVs. But deubiquitylation is not required for all cargos [18]. Several alternative mechanisms, so-called non-canonical ESCRT-dependent pathways, recruit ESCRT-III and ATPase VPS4 to capture cargos

Read the complete text